ClinicalTrials.gg
CompletedNCT01421511Updated Aug 29, 2018Results posted

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Phase 3 interventional study of TR-701 FA and Linezolid in Skin and Subcutaneous Tissue Bacterial Infections, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 118 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.

Sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults. Patients are to start treatment with at least 2 IV doses and may receive IV therapy for the entire treatment duration.

Approximately 100 to 140 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment.

Read the detailed description

The primary objective is to determine the noninferiority (NI) in the early clinical response rate of intravenous (IV) to oral 6 day TR-701 free acid (FA) compared with that of IV to oral 10-day linezolid treatment at 48-72 hours after the first infusion of study drug in the intent-to-treat (ITT) analysis set in patients with acute bacterial skin and skin structure infections (ABSSSI).

02

Conditions studied

  • Skin and Subcutaneous Tissue Bacterial Infections

Keywords

  • ABSSSI
  • Tedizolid Phosphate
  • TR-701
  • Acute Bacterial Skin and Skin Structure Infections
03

In context

Lead sponsor

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 19 studies on the registry; none are open to participants now.

First submitted before Trius Therapeutics LLC became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients requiring IV antibiotic therapy and with systemic signs of infection diagnosed with ABSSSI.
  • Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections

Exclusion criteria

Exclusion Criteria:

  • Uncomplicated skin infections
  • Severe sepsis or septic shock
  • ABSSSI solely due to gram-negative pathogens
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
666 participants (actual)

Study arms

  • Experimental
    TR-701 FA

    • TR-701 FA IV followed by TR-701 FA tablets

    Drug: TR-701 FA

  • Active comparator
    Linezolid

    • Linezolid IV followed by Linezolid Tablets

    Drug: Linezolid

Interventions

  • * TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion * TR-701 FA Tablets, 200 mg, orally once daily

  • * Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion * Linezolid Tablets, 600 mg, orally every 12 hours

06

What researchers measure

Primary outcomes

  1. The Early Clinical Response Rate

    Responder: No increase in lesion surface area from baseline.

    Time frame: 48-72 hours

Secondary outcomes

  1. Clinical Response at the End of Therapy Visit

    Responder: No increase in lesion surface area from baseline.

    Time frame: Day 11

  2. Clinical Response at the End of Therapy Visit in the Clinically Evaluable at End of Therapy Analysis Set

    Responder: No increase in lesion surface area from baseline.

    Time frame: End of Therapy Day 11

  3. Investigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit

    Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, and no further antibiotic therapy required for treatment of primary ABSSSI lesion.

    Time frame: Post-Treatment Evaluation (7-14 days after the End of Therapy)

  4. Investigator's Assessment of Clinical Success of the Post Therapy Evaluation Visit in Clinically Evaluable-Post Treatment Evaluation Analysis Set.

    Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, no new signs, symptoms or complications attributable to the ABSSSI and no further antibiotic therapy required for treatment of primary ABSSSI lesion.

    Time frame: Post-Treatment Evaluation (7-14 days after the End of Therapy)

  5. Investigator's Assessment of Clinical Response at the 48-72 Hour Visit

    Clinical improvement defined as improvement in overall clinical status.

    Time frame: 48-72 Hours

  6. Investigator's Assessment of Clinical Response at the Day-7 Visit

    Clinical improvement defined as improvement in overall clinical status.

    Time frame: Day 7

  7. Change From Baseline in Patient-reported Pain, by Study Visit

    0=no pain, 10=worst pain Only 1 visit per participant for Day 4-6, only 1 visit for Day 7-9, and only 1 visit for Day 10-13.

    Time frame: Multiple

07

Results

Posted Sep 8, 2014
Limitations and caveats
Analyses for this study were conducted using 2 statistical plans, 1 for the US FDA and 1 for the EMA, to address differing guidance on the development of antibacterials. These differences are reflected in the EudraCT and clinicaltrials.gov records.

Participant flow

Participant flow — Overall Study
MilestoneTedizolid PhosphateLinezolid
Started332334
Completed313306
Not completed1928
Withdrew: Lost to follow-up1114
Withdrew: Randomized but didn't receive study drug17
Withdrew: Physician decision01
Withdrew: Withdrawal by subject65
Withdrew: Death11

Outcome measures

PrimaryThe Early Clinical Response Rate

Responder: No increase in lesion surface area from baseline.

Time frame:
48-72 hours
Reported as:
Number · participants
The Early Clinical Response Rate
participantsTedizolid PhosphateLinezolid
The Early Clinical Response Rate283276
Statistical analysis
  • Tedizolid Phosphate vs Linezolid · Risk difference (rd): 2.6 · 95% CI -3.0 to 8.2Risk difference corresponds to the tedizolid responder rate minus the linezolid responder rate.
SecondaryClinical Response at the End of Therapy Visit

Responder: No increase in lesion surface area from baseline.

Time frame:
Day 11
Reported as:
Number · participants
Clinical Response at the End of Therapy Visit
participantsTedizolid PhosphateLinezolid
Clinical Response at the End of Therapy Visit289294
Statistical analysis
  • Tedizolid Phosphate vs Linezolid · Risk difference (rd): -1.0 · 95% CI -6.1 to 4.1Risk difference corresponds to the tedizolid clinical response rate minus the linezolid clinical response rate.
SecondaryClinical Response at the End of Therapy Visit in the Clinically Evaluable at End of Therapy Analysis Set

Responder: No increase in lesion surface area from baseline.

Time frame:
End of Therapy Day 11
Reported as:
Number · participants
Clinical Response at the End of Therapy Visit in the Clinically Evaluable at End of Therapy Analysis Set
participantsTedizolid PhosphateLinezolid
Clinical Response at the End of Therapy Visit in the Clinically Evaluable at End of Therapy Analysis Set272280
Statistical analysis
  • Tedizolid Phosphate vs Linezolid · Risk difference (rd): -4.1 · 95% CI -8.8 to 0.3Risk difference corresponds to the tedizolid clinical response rate minus the linezolid clinical response rate.
SecondaryInvestigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit

Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, and no further antibiotic therapy required for treatment of primary ABSSSI lesion.

Time frame:
Post-Treatment Evaluation (7-14 days after the End of Therapy)
Reported as:
Number · participants
Investigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit
participantsTedizolid PhosphateLinezolid
Investigator's Assessment of Clinical Success at the Post Treatment Evaluation Visit292293
Statistical analysis
  • Tedizolid Phosphate vs Linezolid · Risk difference (rd): 0.3 · 95% CI -4.8 to 5.3Risk difference corresponds to the tedizolid clinical success rate minus the linezolid clinical success rate.
SecondaryInvestigator's Assessment of Clinical Success of the Post Therapy Evaluation Visit in Clinically Evaluable-Post Treatment Evaluation Analysis Set.

Clinical success defined as resolution/near resolution of disease specific signs and symptoms, absence/near resolution of baseline systemic signs of infection, no new signs, symptoms or complications attributable to the ABSSSI and no further antibiotic therapy required for treatment of primary ABSSSI lesion.

Time frame:
Post-Treatment Evaluation (7-14 days after the End of Therapy)
Reported as:
Number · participants
Investigator's Assessment of Clinical Success of the Post Therapy Evaluation Visit in Clinically Evaluable-Post Treatment Evaluation Analysis Set.
participantsTedizolid PhosphateLinezolid
Investigator's Assessment of Clinical Success of the Post Therapy Evaluation Visit in Clinically Evaluable-Post Treatment Evaluation Analysis Set.268269
Statistical analysis
  • Tedizolid Phosphate vs Linezolid · Risk difference (rd): -3.7 · 95% CI -7.7 to 0.2Risk difference corresponds to the tedizolid clinical success rate minus the linezolid clinical success rate.
SecondaryInvestigator's Assessment of Clinical Response at the 48-72 Hour Visit

Clinical improvement defined as improvement in overall clinical status.

Time frame:
48-72 Hours
Reported as:
Number · participants
Investigator's Assessment of Clinical Response at the 48-72 Hour Visit
participantsTedizolid PhosphateLinezolid
Investigator's Assessment of Clinical Response at the 48-72 Hour Visit304302
Statistical analysis
  • Tedizolid Phosphate vs Linezolid · Risk difference (rd): 1.2 · 95% CI -3.3 to 5.6Risk difference corresponds to the tedizolid clinical response rate minus the linezolid clinical response rate.
SecondaryInvestigator's Assessment of Clinical Response at the Day-7 Visit

Clinical improvement defined as improvement in overall clinical status.

Time frame:
Day 7
Reported as:
Number · participants
Investigator's Assessment of Clinical Response at the Day-7 Visit
participantsTedizolid PhosphateLinezolid
Investigator's Assessment of Clinical Response at the Day-7 Visit309308
Statistical analysis
  • Tedizolid Phosphate vs Linezolid · Risk difference (rd): 0.9 · 95% CI -3.2 to 4.9Risk difference corresponds to the tedizolid clinical response rate minus the linezolid clinical response rate.
SecondaryChange From Baseline in Patient-reported Pain, by Study Visit

0=no pain, 10=worst pain Only 1 visit per participant for Day 4-6, only 1 visit for Day 7-9, and only 1 visit for Day 10-13.

Time frame:
Multiple
Reported as:
Mean · units on a scale
Change From Baseline in Patient-reported Pain, by Study Visit
units on a scaleTedizolid PhosphateLinezolid
Day 2-1.7 ± 2.05-2.1 ± 2.29
Day 4-6-3.1 ± 2.67-3.3 ± 2.56
Day 7-9-4.9 ± 2.89-4.9 ± 2.96
Day 10-13-5.4 ± 2.80-5.6 ± 2.84

Adverse events

Collected over Collected from signing of the ICF through the late follow-up visit (up to 38 days).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tedizolid Phosphate—7/331 (2.1%)84/331 (25.4%)
Linezolid—9/327 (2.8%)90/327 (27.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventTedizolid PhosphateLinezolid
CellutitisInfections and infestations0/3312/327
Acute coronary syndromeCardiac disorders0/3311/327
Acute myocardial infarctionCardiac disorders0/3311/327
Anaphylactic reactionImmune system disorders0/3311/327
Meningitis tuberculousInfections and infestations0/3311/327
Urinary tract infection bacterialInfections and infestations0/3311/327
Blood glucose increasedInvestigations0/3311/327
Thrombophlebitis superficialVascular disorders0/3311/327
Myocardial infarctionCardiac disorders1/3310/327
Escherichia urinary tract infectionInfections and infestations1/3310/327
Most frequent other events
Most frequent other events
EventTedizolid PhosphateLinezolid
NauseaGastrointestinal disorders26/33136/327
HeadacheNervous system disorders20/33122/327
DiarrhoeaGastrointestinal disorders11/33117/327
VomitingGastrointestinal disorders10/33117/327
AbscessInfections and infestations14/33110/327
CellulitisInfections and infestations9/3316/327
FatigueGeneral disorders8/3317/327
Vulvovaginal mycotic infectionInfections and infestations2/3317/327
DizzinessNervous system disorders4/3317/327

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Tedizolid PhosphateLinezolidTotal
Mean45.6 ± 15.7945.6 ± 15.5745.6 ± 15.67
Sex: Female, Male
Sex: Female, Male(Participants)Tedizolid PhosphateLinezolidTotal
Female107120227
Male225214439
08

Study locations

118 sites
  • Trius investigator site 159
    Dothan, Alabama 36305, United States
  • Trius investigator site 103
    Chula Vista, California 91911, United States
  • Trius investigator site 143
    Escondido, California 92025, United States
  • Trius investigator site 105
    La Mesa, California 91942, United States
  • Trius investigator site 106
    Long Beach, California 90813, United States
  • Trius investigator site 157
    Long Beach, California 90813, United States
  • Trius investigator site 142
    National City, California 91950, United States
  • Trius investigator site 170
    San Diego, California 92123, United States
  • Trius investigator site 167
    Santa Ana, California 92701, United States
  • Trius investigator site 168
    Stockton, California 95204, United States
  • Trius investigator site 141
    Sylmar, California 91342, United States
  • Trius investigator site 139
    Denver, Colorado 80218, United States
  • Trius investigator site 137
    Newark, Delaware 19718, United States
  • Trius investigator site 166
    Edgewater, Florida 32132, United States
  • Trius investigator site 101
    Columbus, Georgia 31904, United States
  • Trius investigator site 138
    Carmel, Indiana 46032, United States
  • Trius investigator site 144
    Owensboro, Kentucky 42303, United States
  • Trius investigator site 150
    Baton Rouge, Louisiana 70809, United States
  • Trius investigator site 165
    Eunice, Louisiana 70535, United States
  • Trius investigator site 154
    Boston, Massachusetts 02115, United States
  • Trius investigator site 146
    Springfield, Massachusetts 01199, United States
  • Trius investigator site 136
    West Roxbury, Massachusetts 02132, United States
  • Trius investigator site 163
    Royal Oak, Michigan 48073, United States
  • Trius investigator site 153
    Minneapolis, Minnesota 55415, United States
  • Trius investigator site 149
    Picayune, Mississippi 39466, United States
  • Trius investigator site 164
    Creve Coeur, Missouri 63141, United States
  • Trius investigator site 160
    Las Vegas, Nevada 89169, United States
  • Trius investigator site 147
    Teaneck, New Jersey 07666, United States
  • Trius investigator site 140
    Columbus, Ohio 43215, United States
  • Trius investigator site 162
    Lima, Ohio 45801, United States
  • Trius investigator site 161
    Rapid City, South Dakota 57702, United States
  • Trius investigator site 155
    Franklin, Tennessee 37064, United States
  • Trius investigator site 145
    Memphis, Tennessee 38104, United States
  • Trius investigator site 169
    Smyrna, Tennessee 37167, United States
  • Trius investigator site 148
    Houston, Texas 77030, United States
  • Trius investigator site 352
    Cludadela, Buenos Aires B1702FWM, Argentina
  • Trius investigator site 354
    General Roriquez, Buenos Aires B1748, Argentina
  • Trius investigator site 350
    La Plata, Buenos Aires B1900AXI, Argentina
  • Trius investigator site 350
    La Plata, Buenos Aires, Argentina
  • Trius investigator site 353
    Lujan, Buenos Aires B6700AOJ, Argentina
  • Trius investigator site 354
    Buenos Aires, Argentina
  • Trius investigator site 355
    Buenos Aires, Argentina
  • Trius investigator site 351
    Cludad Autonoma De Buenos Aires, C1155AHD, Argentina
  • Trius investigator site 358
    La Plata, Argentina
  • Trius investigator site 357
    Mar del Plata, Argentina
  • Trius investigator site 359
    Paraná, Entre Rios, Argentina
  • Trius investigator site 356
    Rosario, Argentina
  • Trius investigator 500
    Cairns, Queensland 4870, Australia
  • Trius investigator 501
    Herston, Queensland 4029, Australia
  • Trius investigator 503
    Nambour, Queensland 4560, Australia
  • Trius investigator 506
    Southport, Queensland 4215, Australia
  • Trius investigator 502
    Woolloongabba, Queensland 4102, Australia
  • Trius investigator 504
    Woolloongabba, Queensland 4102, Australia
  • Trius investigator 505
    Richmond, Victoria 2131, Australia
  • Trius investigator site 362
    Belo Horizonte, MG, Brazil 30110-934, Brazil
  • Trius investigator site 361
    Belo Horizonte, MG, Brazil 30140-062, Brazil
  • Trius investigator site 363
    Porto Alegre, RS, Brazil 90110-270, Brazil
  • Trius investigator site 364
    Campinas, SP, Brazil 13060-904, Brazil
  • Trius investigator site 361
    Belo Horizonte, Brazil
  • Trius investigator site 362
    Belo Horizonte, Brazil
  • Trius investigator site 365
    Belo Horizonte, Brazil
  • Trius investigator site 364
    Campinas, Brazil
  • Trius investigator site 366
    Curitiba, Brazil
  • Trius investigator site 367
    Curitiba, Brazil
  • Trius investigator site 369
    Jaú, Brazil
  • Trius investigator site 363
    Porto Alegre, Brazil
  • Trius investigator site 370
    Porto Alegre, Brazil
  • Trius investigator site 360
    São Paulo, Brazil
  • Trius investigator site 206
    Quedlinburg, Sachsen-Anhalt 06484, Germany
  • Trius investigator site 208
    Dresden, Sachsen 01307, Germany
  • Trius investigator site 204
    Luebeck, Schleswig-Holstein 23538, Germany
  • Trius investigator site 207
    Berlin, 10249, Germany
  • Trius investigator site 205
    Hamburg, 20246, Germany
  • Trius investigator site 380
    Guadalajara, Mexico
  • Trius investigator site 381
    Guadalajara, Mexico
  • Trius investigator site 382
    Mexico, DF, Mexico
  • Trius investigator site 383
    Monterrey, Mexico
  • Trius investigator 521
    Otahuhu, Auckland, New Zealand
  • Trius investigator 520
    Sydenham, Christchurch 8024, New Zealand
  • Trius investigator site 216
    Bydgoszcz, 85-094, Poland
  • Trius investigator site 211
    Lodz, 93-513, Poland
  • Trius investigator site 214
    Lublin, 20-081, Poland
  • Trius investigator site 213
    Poznan, 60-631, Poland
  • Trius investigator site 215
    Szczecin, 70-111, Poland
  • Trius investigator site 212
    Warszawa, 02-097, Poland
  • Trius investigator site 292
    Vsevolozhsk, Leningrad Region 188640, Russian Federation
  • Trius investigator site 287
    Barmaul, 656024, Russian Federation
  • Trius investigator site 286
    Irkutsk, 664079, Russian Federation
  • Trius investigator site 293
    Lipetsk, 389035/398005, Russian Federation
  • Trius investigator site 295
    Moscow, 115093, Russian Federation
  • Trius investigator site 290
    Moscow, 115280, Russian Federation
  • Trius investigator site 291
    Moscow, 115280, Russian Federation
  • Trius investigator site 288
    Moscow, 119435, Russian Federation
  • Trius investigator site 297
    Novosibirsk, 630008, Russian Federation
  • Trius investigator site 285
    Novosibirsk, 630051, Russian Federation
  • Trius investigator site 294
    saint-Petersburg, 194291, Russian Federation
  • Trius investigator site 289
    Saint-Petersburg, 198099, Russian Federation
  • Trius investigator site 296
    Saint-Petersburg, Russian Federation
  • Trius investigator site 289
    St-Petersburg, 198099, Russian Federation
  • Trius investigator site 298
    Tomsk, 634063, Russian Federation

Showing the first 100 of 118 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sandison T, De Anda C, Fang E, Das AF, Prokocimer P. Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02687-16. doi: 10.1128/AAC.02687-16. Print 2017 May. PubMed 28264845 ↗
  • Nathwani D, Corey R, Das AF, Sandison T, De Anda C, Prokocimer P. Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials. Clin Infect Dis. 2017 Jan 15;64(2):214-217. doi: 10.1093/cid/ciw750. Epub 2016 Dec 21. PubMed 28003218 ↗
  • Powers JH 3rd, Das AF, De Anda C, Prokocimer P. Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain. Contemp Clin Trials. 2016 Sep;50:265-72. doi: 10.1016/j.cct.2016.08.010. Epub 2016 Aug 13. PubMed 27530088 ↗
  • Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015 Feb;59(2):864-71. doi: 10.1128/AAC.03688-14. Epub 2014 Nov 24. PubMed 25421472 ↗
  • Lodise TP, Fang E, Minassian SL, Prokocimer PG. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014 Dec;58(12):7198-204. doi: 10.1128/AAC.03509-14. Epub 2014 Sep 22. PubMed 25246392 ↗
  • Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5. PubMed 24909499 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2011 to primary completion in Jan 2013, 15 months.

Results were first posted in Sep 2014, 1 year 7 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2011
First posted
Aug 22, 2011
StartActual
Sep 15, 2011
Primary completionActual
Jan 10, 2013
CompletionActual
Jan 10, 2013
Results delay requested
Apr 2, 2014
Results first posted
Sep 8, 2014
Last update
Aug 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01421511
Responsible party
Sponsor
First posted
Aug 22, 2011
Start date
Sep 15, 2011
Primary completion
Jan 10, 2013
Completion
Jan 10, 2013
Results posted
Sep 8, 2014
Last update
Aug 29, 2018

Study contacts

Philippe G Prokocimer, MD
study director · Trius Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion